Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17640894 | 0.87 | NOTUM (0.48) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL14955783 | 0.87 | NOTUM (0.48) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL30104024 | 0.79 | NOTUM (0.42) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL6209994 | 0.79 | MAPT (0.43) | NOTUMKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL387290 | 0.79 | MAPT (0.47) | NOTUMKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL23702605 | 0.79 | NOTUM (0.42) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL15652439 | 0.79 | NOTUM (0.42) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| Hydrochloric Acid SCHEMBL11484961 | 0.77 | MAPT (0.46) | NOTUMKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL29080878 | 0.75 | NOTUM (0.48) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL6209396 | 0.75 | NOTUM (0.39) | ADORA2AADORA3ADORA2BADORA1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| WO-2024254537-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254539-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | ADORA2A 1284/4885ADORA3 771/4885ADORA2B 1988/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | ADORA2A 1075/4885ADORA3 1074/4885ADORA2B 431/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | ADORA2A 4403/4885ADORA3 4517/4885ADORA2B 4495/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | ADORA2A 3723/4885ADORA3 3766/4885ADORA2B 4118/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | ADORA2A 2682/4885ADORA3 1485/4885ADORA2B 3460/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | ADORA2A 3966/4885ADORA3 4247/4885ADORA2B 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.